Jagsonpal Pharma
Ticker > Company >

Jagsonpal Pharma share price

Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM BSE: 507789 SECTOR: Pharmaceuticals & Drugs  48k   145   16

591.65
+13.55 (2.34%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 603.5

Today's Low

₹ 565

52 Week High

₹ 634.95

52 Week Low

₹ 270.05

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1568.76 Cr.

Enterprise Value

₹ 1420.82 Cr.

No. of Shares

2.65 Cr.

P/E

64.56

P/B

7.96

Face Value

₹ 5

Div. Yield

0.84 %

Book Value (TTM)

₹  74.34

CASH

₹ 147.93 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

67.97 %

EPS (TTM)

₹  9.16

Sales Growth

-11.83%

ROE

14.02 %

ROCE

17.72%

Profit Growth

-15.94 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.83%
3 Year3.55%
5 Year4.58%

Profit Growth

1 Year-15.94%
3 Year9.61%
5 Year25.5%

ROE%

1 Year14.02%
3 Year16.06%
5 Year14.35%

ROCE %

1 Year17.72%
3 Year21.04%
5 Year18.4%

Debt/Equity

0

Price to Cash Flow

44.61

Interest Cover Ratio

37.6941

CFO/PAT (5 Yr. Avg.)

1.38588074834271

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 67.97 0.00
Jun 2024 68.04 0.00
Mar 2024 68.09 0.00
Dec 2023 68.48 0.00
Sep 2023 68.71 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 21.0357744424048% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 37.6941.
  • The company has an efficient Cash Conversion Cycle of -0.266400000000004 days.
  • Company has a healthy liquidity position with current ratio of 6.8953.
  • The company has a good cash flow management; CFO/PAT stands at 1.38588074834271.
  • The company has a high promoter holding of 67.97%.

 Limitations

  • The company has shown a poor profit growth of 9.60844160043988% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.55347191047168% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 36.8228.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 57.83 47.23 43.49 61.44 74.69
Total Expenditure 49.46 43.84 40.82 51.2 58.41
Operating Profit 8.37 3.4 2.67 10.24 16.29
Other Income 2.27 2.52 2.49 1.44 1.65
Interest 0.22 0.23 0.22 0.22 0.23
Depreciation 0.46 0.41 0.4 1.07 2.34
Exceptional Items 0 0 0 -3.29 0
Profit Before Tax 9.96 5.28 4.54 7.11 15.37
Tax 2.49 1.32 0.99 1.78 3.91
Profit After Tax 7.47 3.96 3.55 5.33 11.46
Adjusted EPS (Rs) 2.85 1.51 1.34 2.01 4.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 158.57 187.95 217.58 236.71 208.7
Total Expenditure 150.04 168.87 192.56 202.56 185.64
Operating Profit 8.53 19.08 25.03 34.15 23.07
Other Income 2.53 4.39 3.43 5.73 9.28
Interest 0.51 0.51 0.29 0.41 0.81
Depreciation 1.13 1.09 1.53 1.21 1.66
Exceptional Items 0 0 0 -3.46 0
Profit Before Tax 9.41 21.87 26.64 34.81 29.87
Tax 1.54 4.81 7.79 8.09 7.41
Net Profit 7.87 17.06 18.86 26.72 22.46
Adjusted EPS (Rs.) 3 6.51 7.2 10.2 8.5

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 13.1 13.1 13.1 13.1 13.22
Total Reserves 97.93 108.83 119.66 145.79 174.18
Borrowings 0 0 0 0 0
Other N/C liabilities 3.09 1.88 4.49 8.49 10.55
Current liabilities 34.57 40.4 34.14 35.18 27.64
Total Liabilities 148.69 164.2 171.4 202.56 225.59
Assets
Net Block 24.44 25.72 22.6 24.28 9.3
Capital WIP 1.9 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 11.39 12.06 28.86 1.12 0
Loans & Advances 14.53 5.66 1.07 0.69 1.72
Other N/C Assets 0.13 0.29 2.62 4.29 23.99
Current Assets 96.31 120.48 116.25 172.17 190.59
Total Assets 148.69 164.2 171.4 202.56 225.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 9.41 21.87 26.64 34.81 29.87
Adjustment -0.57 -2.09 -1.4 9.63 8.27
Changes in Assets & Liabilities 4.84 11.59 -11.46 9.5 5.54
Tax Paid -1.8 -3.15 -6.87 -7.28 -8.51
Operating Cash Flow 11.89 28.22 6.91 46.66 35.17
Investing Cash Flow -11.07 -2.26 -25.78 -57.67 -24.55
Financing Cash Flow -1.82 -6.83 -17.55 -0.46 -8.91
Net Cash Flow -1.01 19.13 -36.42 -11.47 1.71

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 68.71 68.48 68.09 68.04 67.97
aresko progressive privat... 20.36 20.29 20.18 20.16 20.14
infinity holdings 25.24 25.16 25.01 25.00 16.66
infinity holdings sidecar... 18.15 18.09 17.99 17.97 17.95
infinity portfolio holdin... - - - - 8.64
rajpal singh kochhar 4.63 4.61 4.58 4.58 4.58
infinity consumer holding... 0.33 0.33 0.33 0.33 -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 31.29 31.52 31.91 31.96 32.03
authum investment and inf... - - 1.46 1.46 1.46
investor education and pr... 1.56 - - 1.55 1.54
lincoln p coelho 1.18 - 1.17 - 1.17
mukul mahavir agrawal 1.77 - 1.75 - 1.75
sanjiv kumar dudeja 1.41 - 1.40 - 1.40
manish gupta 1.62 1.62 1.92 2.30 -
vanaja sundar iyer 2.01 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Jagsonpal Pharmaceuticals informs about press release 25 Oct, 5:23 PM Jagsonpal Pharmaceuticals informs about revised investor presentation 24 Oct, 12:05 PM Jagsonpal Pharma - Quaterly Results 23 Oct, 6:05 PM Jagsonpal Pharma - Quaterly Results 23 Oct, 6:05 PM Jagsonpal Pharmaceuticals informs about disclosure 18 Sep, 12:18 PM Jagsonpal Pharmaceuticals informs about appointment of investor relation agency 3 Sep, 2:55 PM Jagsonpal Pharma - Quaterly Results 7 Aug, 6:42 PM Jagsonpal Pharma - Quaterly Results 7 Aug, 6:42 PM Jagsonpal Pharma - Quaterly Results 7 Aug, 6:42 PM Jagsonpal Pharmaceuticals informs about press release 24 May, 9:52 AM Jagsonpal Pharmaceutical launches India’s first hormone replacement therapy ‘MemUp’ 24 May, 9:27 AM Jagsonpal Pharma - Quaterly Results 20 May, 7:19 PM Jagsonpal Pharma - Quaterly Results 20 May, 7:19 PM Jagsonpal Pharmaceuticals launches ‘QueeZy-ER’ 9 Mar, 2:45 PM Jagsonpal Pharmaceuticals informs about press release 8 Mar, 5:19 PM Jagsonpal Pharmaceutical launches QueeZy-ER 8 Mar, 4:54 PM Jagsonpal Pharma - Quaterly Results 2 Feb, 5:24 PM Jagsonpal Pharma - Quaterly Results 2 Feb, 5:24 PM Jagsonpal Pharma - Quaterly Results 2 Feb, 5:24 PM Jagsonpal Pharma - Quaterly Results 3 Nov, 1:58 PM Jagsonpal Pharma - Quaterly Results 3 Nov, 1:58 PM Jagsonpal Pharma - Quaterly Results 3 Nov, 1:58 PM Jagsonpal Pharmaceuticals informs about trading window closure 29 Sep, 5:25 PM Jagsonpal Pharmaceuticals informs about voting results of AGM 1 Sep, 3:12 PM Jagsonpal Pharma - Quaterly Results 2 Aug, 6:16 PM Jagsonpal Pharma - Quaterly Results 2 Aug, 6:16 PM Jagsonpal Pharma - Quaterly Results 23 May, 2:44 PM Jagsonpal Pharma - Quaterly Results 23 May, 2:44 PM Jagsonpal Pharma - Quaterly Results 23 May, 2:44 PM Jagsonpal Pharma - Quaterly Results 8 Feb, 8:08 PM Jagsonpal Pharma - Quaterly Results 8 Feb, 8:08 PM Jagsonpal Pharma - Quaterly Results 9 Nov, 7:09 PM Jagsonpal Pharma - Quaterly Results 9 Nov, 7:09 PM Jagsonpal Pharmaceuticals informs about allotment of ESOP 19 Sep, 9:51 AM Jagsonpal Pharma - Quaterly Results 9 Aug, 7:35 PM Jagsonpal Pharma - Quaterly Results 9 Aug, 7:35 PM Jagsonpal Pharmaceuticals informs about certificate 20 Jul, 9:54 AM Jagsonpal Pharmaceuticals informs about change in KMPs 16 Jul, 3:11 PM Jagsonpal Pharmaceuticals informs about letter of offer 31 May, 4:34 PM Jagsonpal Pharma - Quaterly Results 30 May, 6:30 PM Jagsonpal Pharma - Quaterly Results 30 May, 6:30 PM Jagsonpal Pharmaceuticals informs about board meeting 4 May, 9:56 AM Jagsonpal Pharmaceuticals informs about clarification 28 Feb, 4:53 PM Jagsonpal Pharmaceuticals informs about investor presentation 22 Feb, 10:07 AM Jagsonpal Pharmaceuticals enters into agreement with Suvinys Developers 18 Feb, 11:37 AM Jagsonpal Pharmaceuticals informs about supply agreement 18 Feb, 11:32 AM Jagsonpal Pharma - Quaterly Results 11 Feb, 1:37 PM Jagsonpal Pharma - Quaterly Results 11 Feb, 1:37 PM Jagsonpal Pharmaceuticals informs about compliance certificate 13 Jan, 1:46 PM Jagsonpal Pharmaceuticals informs about record date for purpose of interim dividend 20 Oct, 1:08 PM

Jagsonpal Pharma Stock Price Analysis and Quick Research Report. Is Jagsonpal Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jagsonpal Pharma and its performance over the period of time. Jagsonpal Pharma stock price today is Rs 592.6.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jagsonpal Pharma cash from the operating activity was Rs 35.166 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jagsonpal Pharma has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jagsonpal Pharma , the EPS growth was -16.6977 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jagsonpal Pharma has OPM of 11.05260131671 % which is a bad sign for profitability.
     
  • ROE: Jagsonpal Pharma have a average ROE of 14.0194 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jagsonpal Pharma is Rs 592.6. One can use valuation calculators of ticker to know if Jagsonpal Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Jagsonpal Pharma

Jagsonpal Pharmaceuticals Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Jagsonpal Pharmaceuticals Limited (JPL) is a leading pharmaceutical company in India that develops and sells a range of branded and generic drugs across various specialties such as antibiotics, anti-inflammatory, and analgesics, among others. The company was founded in 1970 and its headquarters are located in New Delhi, India.

Jagsonpal Pharmaceuticals Limited : Share Price

JPL is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India. Its share price has been gradually increasing over the past few years, reflecting the company's strong financial performance and growth prospects. You can find real-time and historical share price data on our website, along with various charts and analysis tools to help you make informed investment decisions.

Jagsonpal Pharmaceuticals Limited : Balance Sheet

JPL's balance sheet is a strong indicator of the company's financial health and ability to weather economic downturns. Our website provides you with comprehensive balance sheet data for JPL, including information on assets, liabilities, and shareholder equity. Additionally, our users can access premium tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis to calculate the company's fair value.

Jagsonpal Pharmaceuticals Limited : Annual Report

JPL's annual report provides investors with a detailed overview of the company's financial performance, growth plans, and strategic initiatives. Our website provides you with downloadable versions of JPL's annual reports, as well as other research reports, credit ratings, and investor presentations.

Jagsonpal Pharmaceuticals Limited :  Dividend

JPL has a consistent track record of paying dividends to its shareholders, reflecting the company's strong financial performance and healthy cash flow. Our website provides you with historical dividend data for JPL, along with other key financial metrics such as earnings per share (EPS) and return on equity (ROE), to help you make informed investment decisions.

Jagsonpal Pharmaceuticals Limited : Quarterly Result

JPL's quarterly results provide investors with a more frequent update on the company's financial performance and operational metrics. Our website provides comprehensive quarterly result data for JPL, including information on revenue, profit margins, and earnings. Additionally, users can use our pre-built screening tools to compare JPL's performance against other companies in the pharmaceutical sector.

Jagsonpal Pharmaceuticals Limited : Stock Price

JPL's stock price is influenced by a range of factors including the company's financial performance, industry trends, and macroeconomic conditions. Our website provides real-time and historical stock price data for JPL, along with various charts and analysis tools to help you track the company's performance. Additionally, our platform provides various screening tools to help you find stocks that meet your investment criteria.

Jagsonpal Pharmaceuticals Limited : Price Chart

Our website provides you with comprehensive price charts for JPL, which allow you to track the company's stock performance over various time periods. You can customize the charts according to your preferences, including adding technical indicators and other analysis tools. These charts help long-term investors to understand the stock's movement.

Jagsonpal Pharmaceuticals Limited : News and Concall Transcripts

Our website provides you with the latest news and updates on JPL, including analyst reports, press releases, and management interviews. Additionally, users can access JPL's concall transcripts and earn management's insights on various aspects of the company's performance.

Jagsonpal Pharmaceuticals Limited : Investor Presentations

Our website provides downloads of JPL's investor presentations, which provide a detailed overview of the company's financial performance, growth plans, and strategic initiatives. These presentations are a valuable resource for investors looking to understand JPL's positioning within the pharmaceutical sector and evaluate the potential for future growth.

Jagsonpal Pharmaceuticals Limited :  Promoters

JPL's promoters have a long-standing track record of success within the pharmaceutical industry, and their leadership has been instrumental in driving the company's growth and success. Our website provides downloadable data on JPL's promoter holdings as well as insider trading information.

Jagsonpal Pharmaceuticals Limited :  Shareholders

JPL has a diverse shareholder base that includes institutional investors, retail investors, and individual shareholders. Our website provides data on JPL's major shareholders, as well as information on shareholding patterns, and other key ownership metrics for users to analyse. Additionally, our users can use our pre-built screening tools to compare JPL's ownership structure with other companies within the pharmaceutical sector.

Read More
X